Immatics (IMTX) Stock Price, News & Analysis

Company Overview

Immatics (NASDAQ: IMTX) is a clinical-stage biopharmaceutical company focused on the development of next-generation T-cell receptor (TCR) based immunotherapies for the treatment of patients with cancer. The company leverages its proprietary platforms to identify tumor-specific antigens and engineer affinity-enhanced TCRs that are capable of recognizing and eliminating cancer cells. Immatics’ research and development activities span target discovery, TCR isolation, preclinical validation, and the manufacturing of investigational therapeutic candidates.

At the core of Immatics’ pipeline are two complementary technology platforms. The first platform centers on engineered autologous TCR-T cell therapies, in which patients’ own immune cells are genetically modified to express high-affinity TCRs against selected tumor targets. The second platform comprises proprietary TCR-based bispecific molecules designed to recruit and activate polyclonal T cells in a tumor-selective manner. Immatics is advancing multiple programs across a range of solid tumor indications, with several candidates currently in early-stage clinical trials.

Founded in 2000 and headquartered in Tübingen, Germany, with U.S. operations in Houston, Texas, Immatics has built an integrated R&D infrastructure that includes high-throughput antigen discovery, TCR screening, bioinformatics, and cell and molecular biology. The company fosters strategic partnerships with leading pharmaceutical companies to accelerate program development and broaden the reach of its technology. Immatics’ global footprint supports collaborations, manufacturing scale-up, and clinical trial execution across Europe and North America.

Immatics is led by an experienced management team with extensive expertise in immuno-oncology, cell therapy, and drug development. Under the leadership of Chief Executive Officer Harpreet Singh, the company continues to pursue its mission of harnessing the power of TCRs to create novel, targeted treatments for patients with cancer, while advancing a robust pipeline of therapeutic candidates toward regulatory milestones.

Key Stats

• Today's Range: $5.57 to $5.79
• 50-Day Range: $4.24 to $6.14
• 52-Week Range: $3.30 to $13.09
• Volume: 257,998 shs
• Average Volume: 676,437 shs
• Market Capitalization: $691.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.67
• Consensus Rating: Buy

Immatics Stock Analysis - MarketRank™

Immatics scored higher than 48% of companies evaluated by MarketBeat, and ranked 545th out of 913 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Immatics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Immatics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immatics are expected to decrease in the coming year, from ($0.72) to ($1.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immatics is -33.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immatics is -33.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immatics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.73% of the float of Immatics has been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Immatics has recently decreased by 12.02%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immatics does not currently pay a dividend.

Dividend Growth

Immatics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.73% of the float of Immatics has been sold short.

Short Interest Ratio / Days to Cover

Immatics has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Immatics has recently decreased by 12.02%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for IMTX on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

3 people have added Immatics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Immatics insiders have not sold or bought any company stock.

Percentage Held by Institutions

64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMTX Stock Analysis - Frequently Asked Questions

How have IMTX shares performed this year?

Immatics' stock was trading at $7.11 at the start of the year. Since then, IMTX shares have decreased by 20.8% and is now trading at $5.63.

How were Immatics' earnings last quarter?

Immatics N.V. (NASDAQ:IMTX) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. The business had revenue of $20.12 million for the quarter, compared to analyst estimates of $14.92 million. Immatics had a negative trailing twelve-month return on equity of 4.52% and a negative net margin of 14.73%.

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immatics investors own include Broadcom (AVGO), Datadog (DDOG), Advanced Micro Devices (AMD), Moderna (MRNA), Cloudflare (NET) and QUALCOMM (QCOM).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMTX
• CIK: 1809196
• Web: www.immatics.com
• Phone: 4.97072E+12
• Fax: N/A
• Employees: 260
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.67
• High Stock Price Target: $19.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +160.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $16.47 million
• Net Margins: -14.73%
• Pretax Margin: -11.63%
• Return on Equity: -4.52%
• Return on Assets: -3.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.28
• Quick Ratio: 10.28

Sales & Book Value

• Annual Sales: $168.65 million
• Price / Sales: 4.06
• Cash Flow: $0.24 per share
• Price / Cash Flow: 23.37
• Book Value: $5.12 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 121,550,000
• Free Float: N/A
• Market Cap: $684.33 million
• Optionable: Optionable
• Beta: 0.81